skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Benefits of statin therapy and compliance in high risk cardiovascular patients

Review

(2755) Views  (1241) Full article downloads

Authors: Joel A Lardizabal, Prakash C Deedwania

Published Date September 2010 Volume 2010:6 Pages 843 - 853
DOI: http://dx.doi.org/10.2147/VHRM.S9474

Joel A Lardizabal1, Prakash C Deedwania2
1Division of Cardiology, Department of Medicine, University of California in San Francisco (Fresno-MEP), Fresno, CA, USA; 2University of California in San Francisco, Chief of Cardiology, Veterans Affairs Central California System, Fresno, CA, USA

Abstract: Cardiovascular disease (CVD) remains the top cause of global mortality. There is considerable evidence that supports the mortality and morbidity benefit of statin therapy in coronary heart disease (CHD) and stroke, both in primary and secondary prevention settings. Data also exist pointing to the advantage of statin treatment in other high-risk CVD conditions, such as diabetes, CKD, CHF, and PVD. National and international clinical guidelines in the management of these CVD conditions all advocate for the utilization of statin therapy in appropriate patients. However, overall compliance to statin therapy remains suboptimal. Patient-, physician-, and economic-related factors all play a role. These factors need to be considered in devising approaches to enhance adherence to guideline-based therapies. To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged.

Keywords: cardiovascular disease, statin therapy, coronary heart disease, long-term treatment compliance




 

Other articles by Dr Prakash Deedwania



Readers of this article also read:

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Impact of a diabetic foot care education program on lower limb amputation rate
COSEHC global vascular risk management quality improvement program: rationale and design
Medical treatment and long-term outcome of chronic atrial fibrillation in the aged with chest distress: a retrospective analysis versus sinus rhythm
Lipid-lowering therapy: who can benefit
Lower extremity venous thrombosis in patients younger than 50 years of age
Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University